AVENUE THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
ATXI$0.42-50.7%Stored close · as of Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(2,947) | $(11,696) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Share based compensation | 665 | 1,236 |
| Loss on common stock warrant liabilities | — | 759 |
| Change in fair value of warrant liability | (15) | (170) |
| Common shares issuable - Founders Agreement | 76 | (167) |
| Issuance of common stock to Fortress | 55 | 827 |
| Issuance of subsidiaries’ common shares for license expenses | — | 6 |
| Gain on repurchase of common stock held by AnnJi | (4) | — |
| Issuance of common stock of subsidiary | 37 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 2 | (11) |
| Accounts payable and accrued expenses | (186) | 367 |
| Accounts payable and accrued expenses - related party | 484 | (177) |
| Net cash and cash equivalents used in operating activities | (1,833) | (9,026) |
| Cash flows from financing activities: | ||
| Proceeds from ATM sales of common stock, net of issuance costs | 2,094 | 1,623 |
| Proceeds from exercise of warrants | — | 9,421 |
| Warrant exercise transaction costs | — | (1,207) |
| Net cash provided by financing activities | 2,094 | 9,837 |
| Net change in cash and cash equivalents | 261 | 811 |
| Cash and cash equivalents, beginning of period | 2,594 | 1,783 |
| Cash and cash equivalents, end of period | $2,855 | $2,594 |
| Supplement disclosure of non-cash information: | ||
| Baergic deconsolidation | $(1) | $— |
| Issuance of common shares - Founders Agreement | $55 | $827 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.